


RECEIVED



5 2001

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00		A2	(11) International Publication Number: WO 99/11250
			(43) International Publication Date: 11 March 1999 (11.03.99)
<p>(21) International Application Number: PCT/US98/18284</p> <p>(22) International Filing Date: 3 September 1998 (03.09.98)</p> <p>(30) Priority Data: 60/057,921 4 September 1997 (04.09.97) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): NOVONEU-RON, INC. [US/US]; Suite 399, 1 Northeast 19th Street, Miami, FL 33132 (US).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): MASH, Deborah, C. [US/US]; 7552 W. Treasure Drive, North Bay Village, FL 33141 (US).</p> <p>(74) Agent: SANZO, Michael, A.; Vinson & Elkins, 2300 First City Tower, 1001 Fannin, Houston, TX 77002-6760 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	

(54) Title: NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION

(57) Abstract

The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.